Lv3
210 积分 2022-04-12 加入
Toward Greater Transparency at the FDA—Now Is the Time to Act
28天前
已关闭
Oncology Drug Development: Challenges of Increasingly Available Therapies
29天前
已关闭
Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22
2个月前
已关闭
Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22
2个月前
已关闭
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
2个月前
已完结
Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials
3个月前
已完结
Advancing CAR T-Cell Therapy
4个月前
已完结
Mitigating Limited Data Challenges to Improve Artificial Intelligence Integration in Rare Disease Drug Development
4个月前
已完结
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)
5个月前
已完结
Mitigating Limited Data Challenges to Improve Artificial Intelligence Integration in Rare Disease Drug Development
5个月前
已关闭
皖公网安备34019202002308